Collaborative Development and License Agreement Sample Contracts

COLLABORATIVE DEVELOPMENT AND LICENSE AGREEMENT by and between ENANTA PHARMACEUTICALS, INC. and ABBOTT LABORATORIES November 27, 2006 Confidential materials omitted and filed separately with the Securities and Exchange Commission. Asterisks denote...
Collaborative Development and License Agreement • February 9th, 2016 • Enanta Pharmaceuticals Inc • Pharmaceutical preparations • New York

THIS SERIES E CONVERTIBLE PREFERRED STOCK PURCHASE AGREEMENT (“Agreement”) is made as of [●], 20 , by and among Enanta Pharmaceuticals, Inc., a Delaware corporation (the “Corporation”), the investors named on the Schedule of Investors attached hereto (the “Initial Investors”) and the additional investors added from time to time to the Schedule of Investors in accordance with Section 23 below (the “Additional Investors,” and together with the Initial Investors, the “Investors”).

AutoNDA by SimpleDocs
COLLABORATIVE DEVELOPMENT AND LICENSE AGREEMENT
Collaborative Development and License Agreement • November 4th, 2016 • Immunogen Inc • Pharmaceutical preparations • New York

This COLLABORATIVE DEVELOPMENT AND LICENSE AGREEMENT (this “Agreement”) is entered into as of July 7, 2006 (the “Effective Date”), by and between ImmunoGen, Inc., a Massachusetts corporation with its principal place of business at 128 Sidney Street, Cambridge, Massachusetts, USA 02139 (“ImmunoGen”) and Biotest AG, a corporation organized under the laws of Germany having an address of Landsteinerstraße 5, D-63303 Dreieich, Germany (“Biotest”). Each of Biotest and ImmunoGen is sometimes referred to individually herein as a “Party” and collectively as the “Parties.”

AMENDMENT NO. 2 TO COLLABORATIVE DEVELOPMENT AND LICENSE AGREEMENT
Collaborative Development and License Agreement • February 5th, 2015 • Immunogen Inc • Pharmaceutical preparations

This Amendment No. 2 (this “Amendment No. 2”) to the Collaborative Development and License Agreement entered into as of July 7, 2006 (the “Agreement Effective Date”), as amended as of August 23, 2006 (the “Agreement”) by and between ImmunoGen, a Massachusetts corporation with its principal place of business at 830 Winter Street, Waltham, Massachusetts 02451, USA (“ImmunoGen”) and Biotest AG, a corporation organized under the laws of Germany having an address of Landerstrasse 5, D-63303 Dreieich, Germany (“Biotest”) is dated as of December10, 2014.

AMENDMENT NO. 3 TO COLLABORATIVE DEVELOPMENT AND LICENSE AGREEMENT
Collaborative Development and License Agreement • November 9th, 2017 • Immunogen Inc • Pharmaceutical preparations

This Amendment No. 3 (this “Amendment No. 3”) to the Collaborative Development and License Agreement entered into as of July 7, 2006 (the “Agreement Effective Date”), as amended as of August 23, 2006 and December 10, 2014 (the “Agreement”) by and between ImmunoGen, a Massachusetts corporation with its principal place of business at 830 Winter Street, Waltham, Massachusetts 02451, USA (“ImmunoGen”) and Biotest AG, a corporation organized under the laws of Germany having an address of Landsteinerstrasse 5, D-63303 Dreieich, Germany (“Biotest”) is dated as of October 26, 2017.

Draft better contracts in just 5 minutes Get the weekly Law Insider newsletter packed with expert videos, webinars, ebooks, and more!